Division of Chemistry and Biotechnology, Graduate School of Natural Science and Technology, Okayama University, 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan.
J Med Chem. 2013 Feb 28;56(4):1431-42. doi: 10.1021/jm300887b. Epub 2013 Feb 15.
To obtain a high antimalarial activity with neocryptolepine derivatives, modifying and changing the side chains at the C11 position with varying the substituents of an electron-withdrawing or electron-donating nature at the C2 position for a SAR study were executed. Installation of alkylamino and ω-aminoalkylamino groups at the C11 position of the neocryptolepine core was successful. For further variation, the aminoalkylamino substituents were transformed into the corresponding acyclic or cyclic carbamides or thiocarbamides. These side chain modified neocryptolepine derivatives were tested for antimalarial activity against CQR (K1) and CQS (NF54) of Plasmodium falciparum in vitro and for cytotoxicity toward mammalian L6 cells. Among the tested compounds, the compound 17f showed an IC50 of 2.2 nM for CQS (NF54) and a selectivity index of 1400, and 17i showed an IC50 of 2.2 nM for CQR (K1), a selectivity index of 1243, and a resistance index of 0.5.
为了获得具有高抗疟活性的新隐冬碱衍生物,我们对 C11 位的侧链进行了修饰和改变,通过在 C2 位改变吸电子或供电子取代基来进行 SAR 研究。成功地在新隐冬碱核心的 C11 位安装了烷基氨基和 ω-氨基烷基氨基基团。为了进一步改变,将氨基烷基氨基取代基转化为相应的无环或环状氨基甲酰基或硫代氨基甲酰基。对这些侧链修饰的新隐冬碱衍生物进行了体外抗疟活性测试,针对疟原虫的 CQR (K1) 和 CQS (NF54),以及对哺乳动物 L6 细胞的细胞毒性。在测试的化合物中,化合物 17f 对 CQS (NF54) 的 IC50 为 2.2 nM,选择性指数为 1400,化合物 17i 对 CQR (K1) 的 IC50 为 2.2 nM,选择性指数为 1243,抗性指数为 0.5。